-
Novel Drug Product Creation with new composition-of-Matter IP
Our technology is a powerful Intellectual Property (IP) engine
Topical therapies are the therapeutic pillar for many diseases, but traditional water- or oil-based formulations have significant limitations that may influence efficacy and safety.
EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It dramatically increases the residual time on the eye from seconds to hours and enables high bioavailability of active pharmaceutical ingredients (API) with excellent tolerability and safety while reducing systemic exposure due to a small drop size (<12 µL).
Thereby EyeSol® unlocks the full potential of APIs by generating novel drug products often even with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.
Novaliq Ophthalmic Pipeline
Clinical Development & Marketed Products
EyeSol® Product | Indication | Phase I | Phase II | Phase III | NDA | Market | Next milestone | Sponsor/Partner |
---|---|---|---|---|---|---|---|---|
NovaTears® (perfluorohexyloctane) |
Dry Eye Disease |
![]() |
Geographic expansion |
![]() ![]() |
||||
NovaTears® + Omega-3 (perfluorohexyloctane, omega-3) | Dry Eye Disease |
![]() |
Geographic expansion |
![]() ![]() |
||||
CyclASol® (cyclosporine 0.1%) |
Dry Eye Disease (anti-inflammatory) |
![]() |
U.S. PDUFA date: 8 June 2023 |
![]() |
||||
![]() |
China NDA Submission |
![]() |
||||||
NOV03® (perfluorohexyloctane) |
Dry Eye Disease (associated with MGD) |
![]() |
U.S. PDUFA date: 28 June 2023 |
![]() |
||||
![]() |
China NDA Submission |
![]() |
||||||
BTQ-1902® (timolol 0.5%) |
Dry Eye Disease Pressure (Glaucoma) |
![]() |
Phase III initiation |
![]() |
EyeSol Research Development program in ophthalmology: lipophilic, instable APIs & biologicals
EyeSol® Product | Target indication | Early PC | PoC (MoA) | PoC (PoP) | Pre-IND | IND | ||
---|---|---|---|---|---|---|---|---|
Prostaglandins & combination products |
Elevated Intraocular Pressure (Glaucoma) |
Global R&D
Development Strategy:
Strategically target and
address key issues in ophthalmology therapeutics |
![]() |
|||||
Iodine (molecular) Azithromycin |
Ocular infections | |||||||
Tacrolimus | Non-infectious anterior uveitis | |||||||
Cyclosporine | Ocular allergies | |||||||
Atropine | Progressive myopia | |||||||
Anti-ischemic (small molecule) | Diabetic retinopathy | |||||||
Peptide (undisclosed) | Diabetic retinopathy |
Note: NDA = New Drug Application at US Food and Drug Administration (FDA); MGD = Meibomian Gland Dysfunction; API = Active Pharmaceutical Ingredient.
Approved CE products: Novatears®, Novatears®+Omega-3